Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.
2.

A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.

Solomon N, Mezentsev D, Reis I, Lima M, Rios J, Avisar E, Franceschi D, Livingstone A, Podolsky L, Ardalan B.

Jpn J Clin Oncol. 2011 Apr;41(4):469-76. doi: 10.1093/jjco/hyq239. Epub 2011 Jan 21.

PMID:
21258083
3.

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E.

Lung Cancer. 2006 Sep;53(3):347-53. Epub 2006 Jul 17.

PMID:
16844257
4.

Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer.

Jacot W, Bibeau F, Gourgou-Bourgade S, Gutowski M, Colombo PE, Bleuse JP, Kramar A, Romieu G.

Am J Clin Oncol. 2010 Dec;33(6):544-9. doi: 10.1097/COC.0b013e3181bead47.

PMID:
20042972
5.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
6.

Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.

Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N.

Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4.

PMID:
21684812
7.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
8.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
9.
10.
11.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.

PMID:
24057043
12.
13.

Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.

Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, Michailidis P, Tentes A, Deftereos S, Karanikas M, Karayiannakis A, Kakolyris S.

Oncology. 2011;80(5-6):359-65. doi: 10.1159/000330199. Epub 2011 Jul 29.

PMID:
21811088
14.

The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.

Hirano A, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Okabe T, Kimura K, Kamimura M, Domoto K, Aiba M, Ogawa K.

Anticancer Res. 2006 Jan-Feb;26(1B):581-4.

15.

A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.

Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J.

Clin Cancer Res. 2004 Oct 15;10(20):6764-9.

16.

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.

Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S.

Expert Opin Investig Drugs. 2013 Mar;22(3):299-307. doi: 10.1517/13543784.2013.766715.

PMID:
23394482
17.

A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).

Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, Grossi F.

Eur J Cancer. 2011 Jul;47(11):1653-9. doi: 10.1016/j.ejca.2011.03.020. Epub 2011 Apr 20.

PMID:
21514147
18.

Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.

Ramaswamy B, Povoski SP, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendra K, Somasundaram S, Orlowski RZ, Shapiro CL.

Breast Cancer Res Treat. 2005 Sep;93(1):67-74.

PMID:
16184461
19.

A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.

Zhao L, Bai C, Shao Y, Guan M, Jia N, Xiao Y, Qiu H, Zhang F, Yang T, Zhong G, Chen S.

Cancer Lett. 2011 Nov 28;310(2):134-9. doi: 10.1016/j.canlet.2011.06.026. Epub 2011 Jul 5.

PMID:
21782322
20.

Neoadjuvant chemotherapy with taxotere-epirubicin-5-fluorouracil (TEF) in local-regionally advanced breast cancer: a preliminary report.

Baltali E, Altundağ MK, Onat DA, Abbasoğlu O, Ozişik Y, Güler N, Atahan L, Berberoğlu U, Altinok M, Baran I, Celik I, Tekuzman G.

Tumori. 2002 Nov-Dec;88(6):474-7.

PMID:
12597141

Supplemental Content

Support Center